Rosetta Genomics is expanding its Israeli research facility to include new laboratories for its microRNA-based diagnostic programs. The company expects to grow to approximately 70 employees by the end of the year.
"This expansion will enable us to advance new development programs and accommodate the large number of scientists that have joined Rosetta recently and those we expect to add in the future," says Amir Avniel, CEO. "Our proprietary discovery platform is capable of utilizing over 12,000 predicted and validated microRNAs, including over 1,000 proprietary microRNAs, which are expressed in different tissues. This platform provides us with the foundation upon which we can advance microRNA-based diagnostic products in key oncology indications. The new lab space is essential for the success of these efforts."